Fielmann Group AGCHIX:FIED 84 PB Ratio is 3.63 as of Jun. 26, 2026, which is 46% below its 10-year median of 6.69. GuruFocus rates CHIX:FIED with a GF Score™ of 84/100 and a GF Value™ of €53.71 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Fielmann Group AG ranks worse than 72.46% on this metric.
Fielmann Group AG stock PB Ratio (=3.65) is close to 3-year low of 3.42.
The historical rank and industry rank for Fielmann Group AG's PB Ratio or its related term are showing as below:
CHIX:FIEd'
s PB Ratio Range Over the Past 10 Years
Min: 3.12 Med: 6.69 Max: 10.05
Current: 3.65
During the past 13 years, Fielmann Group AG's highest PB Ratio was 10.05. The lowest was 3.12. And the median was 6.69.
CHIX:FIEd's PB Ratio is ranked worse than 72.46% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.02
vs CHIX:FIEd: 3.65
During the past 12 months, Fielmann Group AG's average Book Value Per Share Growth Rate was 8.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 7.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 4.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 3.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Fielmann Group AG was 11.30% per year. The lowest was 0.50% per year. And the median was 5.00% per year.
Back to Basics: PB Ratio
Fielmann Group AG (CHIX:FIEd) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Fielmann Group AG PB Ratio Related Terms
Fielmann Group AG PB Ratio Historical Data
* Premium members only.
The historical data trend for Fielmann Group AG's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Fielmann Group AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fielmann Group AG PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fielmann Group AG's PB Ratio distribution charts can be found below:
* The bar in red indicates where Fielmann Group AG's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Fielmann Group AG (CHIX:FIED) has a PB Ratio of 3.63 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Fielmann Group AG and its competitors. This is 46% below median its historical median of 6.69. Over the past decade, Fielmann Group AG's PB Ratio has ranged from 3.12 to 10.05. According to the industry distribution chart, Fielmann Group AG ranks #571 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 72.5%.
Is Fielmann Group AG's PB Ratio too high?
Fielmann Group AG's current PB Ratio of 3.63 is 46% below median its 10-year median of 6.69. Over the past 10 years, this metric has ranged from a low of 3.12 to a high of 10.05. The Medical Devices & Instruments industry median PB Ratio is 2.02. Fielmann Group AG's value of 3.63 is 79.7% above this industry median. Based on the distribution chart, Fielmann Group AG ranks #571 out of 788 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Fielmann Group AG has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fielmann Group AG's PB Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fielmann Group AG ranks #571 out of 788 companies for PB Ratio. This places Fielmann Group AG in the lower half of its industry. The industry median PB Ratio is 2.02. Fielmann Group AG's value of 3.63 is 79.7% above this benchmark. Historically, Fielmann Group AG's own PB Ratio has ranged from 3.12 to 10.05 over the past decade. While the company's 10-year median is 6.69 vs. the industry median of 2.02, Fielmann Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.02, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fielmann Group AG's current PB Ratio of 3.63 is 79.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Fielmann Group AG and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fielmann Group AG's current PB Ratio is 3.63, which is 46% below median its own 10-year median of 6.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fielmann Group AG stock overvalued right now?
Based on GuruFocus' analysis, Fielmann Group AG (CHIX:FIED) is currently considered Modestly Undervalued. The stock's GF Value™ is €53.71, compared to a current price of €42.45 — trading 21% below its estimated fair value. The current PB Ratio is 3.63, which is 46% below median its 10-year median of 6.69 and 79.7% above the Medical Devices & Instruments industry median of 2.02. Fielmann Group AG's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Fielmann Group AG (CHIX:FIED), the current PB Ratio is 3.63 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fielmann Group AG (CHIX:FIED) Overvalued in 2026?
Based on GuruFocus' analysis, Fielmann Group AG stock appears to be undervalued.
The current stock price of €42.45 is trading 21% below its estimated GF Value™ of €53.71.
GuruFocus considers Fielmann Group AG to be Modestly Undervalued.
Key valuation signals for CHIX:FIED:
PB Ratio: 3.63 (46% below median its 10-year median of 6.69)
GF Value™: €53.71 vs. price of €42.45 (21% below fair value)
Industry Position: 79.7% above the Medical Devices & Instruments median (#571 of 788)
No single metric tells the full story. See the CHIX:FIED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fielmann Group AG is involved in the purchase and sale of goods, in physical stores as well as wholesale and online, particularly in the optometric and hearing acoustics sectors, and especially sales of all kinds of vision aids - particularly glasses, eyeewear frames and lenses, sunglasses, contact lenses, accessories, hearing systems, as well as personal protective equipment. Fielmann is involved in all levels of the optical industry value-added chain: designing, manufacturing, product offering, and optician services. The group was divided into six segments: Germany, Switzerland, Austria, Spain, North America, and Other. The majority of its revenue is generated from Germany.
84GF Score
Get the complete analysis for CHIX:FIED
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:FIED has been successfully added to your 
